Hansen Pharmaceutical has completed the registration of changes to its Drug Production License and obtained a new license issued by the Hunan Provincial Medical Products Administration. The update mainly involves adjustments to the company head, quality head, and quality authorized person, while other details remain unchanged. The new license is valid until November 6, 2030, with the production address at 2688 Yincheng Avenue, Heshan District, Yiyang City, and the production scope includes large-volume injections, small-volume injections, tablets, and various other drugs. In the first quarter of 2026, Hansen Pharmaceutical achieved revenue of 263 million yuan and net profit attributable to the parent company of 38.41 million yuan.
Hunan Hansen Pharmaceutical Co LtdCompleted registration of changes to Drug Production License, a routine regulatory update with no material impact on operations.